Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx's Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from a previous Phase 1 study of the drug were announced in September 2012. Ablynx President and CEO Edwin Moses recently … [Read more...] about Activaero system used in new Ablynx Phase 1 studies of inhaled Nanobody for RSV
Medical
Study shows feasibility of nasal dosing of diazepam during seizure
Acorda Therapeutics announced results from a clinical study of the pharmacokinetics, safety, and tolerability of its diazepam nasal spray for the treatment of cluster seizures in epilepsy patients at the recent International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE). Over the course of the study, 31 … [Read more...] about Study shows feasibility of nasal dosing of diazepam during seizure
Arikace meets primary endpoint in Phase 3 study
According to Insmed, a Phase 3 study of more than 300 cystic fibrosis patients has demonstrated the non-inferiority of once-daily Arikace inhaled liposomal amikacin to twice-daily TOBI tobramycin inhalation solution, meeting the study's primary endpoint. The company also announced that the FDA has granted Arikace Fast Track and Qualified Infectious Disease Product … [Read more...] about Arikace meets primary endpoint in Phase 3 study
Inspiro reports positive results for Inspiromatic DPI study
Israeli device company Inspiro Medical has announced that a safety and efficacy study of formoterol delivered by the Inspiromatic dry powder inhaler for the treatment of asthma in children met both its primary and secondary endpoints. According to the company, the randomized, crossover, double blind study, which involved 30 asthmatic children, demonstrated … [Read more...] about Inspiro reports positive results for Inspiromatic DPI study
Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company's GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher doses of oral pirfenidone. Genoa said that it would present data at an upcoming pulmonary … [Read more...] about Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study
Johnson & Johnson developing ketamine nasal spray for depression
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company's pipeline drugs in a document dated April 16, 2013 on the J&J website. Reportedly, J&J's nasal spray is a formulation of esketamine, an isomer of … [Read more...] about Johnson & Johnson developing ketamine nasal spray for depression
New nasal research consortium “The Oz Nose Project” announced
A new consortium described as a "series of conceptual research projects in the area of nasal physiology, function and drug delivery" that "aims to enhance understanding in the area of upper respiratory tract disorders and develop methodological approaches that can be utilized via the wider scientific community" has been announced. Researchers involved in the … [Read more...] about New nasal research consortium “The Oz Nose Project” announced
Study shows significant overdiagnosis of COPD
A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth Health Center in Youngstown assessed 80 patients at a health center in Akron, Ohio using spirometry. All of the patients had either been diagnosed with COPD or … [Read more...] about Study shows significant overdiagnosis of COPD
Prosonix begins Phase 2 study of inhaled glycopyrronium bromide
Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered particles is delivered by pMDI. Prosonix CEO David Hipkiss commented, “This trial with PSX1002 is a … [Read more...] about Prosonix begins Phase 2 study of inhaled glycopyrronium bromide
Safety studies show no increased risk with use of Brovana inhalation solution
According to Sunovion Pharmaceuticals, data from a year-long clinical trial comparing the safety of Brovana arformoterol tartrate inhalation solution versus placebo in patients with moderate-to-severe COPD show no increased risk of exacerbations or death due to a respiratory event. Fewer than 10% of patients treated with 15 mcg of Brovana twice daily had serious … [Read more...] about Safety studies show no increased risk with use of Brovana inhalation solution